Coronavirus (COVID-19)
Learn more
April 11, 2017
Sponsor: Merck Sharp & Dohme Corp.
Number: MK-3475-361
The purpose of this study is to determine the efficacy and safety of Pembrolizumab (MK-3475) with or without chemotherapy versus chemotherapy alone. The study is for participants with advanced (infiltrating the musculature) or metastatic (the development of secondary malignant growths at a distance from a primary site of cancer) urothelial carcinoma/bladder cancer. The primary hypotheses are that Pembrolizumab plus chemotherapy is superior to chemotherapy alone with respect to Progression-free Survival (PFS) and Overall Survival (OS) in participants. These participants with programmed cell death ligand 1 (PD-L1), have positive tumors and/or PD-L1 negative tumors.
Who’s eligible:
Available at: Backus Hospital- Eastern Connecticut Hematology and Oncology.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209